Mizuho on Immatics (IMTX): 'Multiple Catalysts on the Horizon; Maintain OP Rating on this PRAME Therapy Leader'
Tweet Send to a Friend
Mizuho analyst Graig Suvannavejh reiterated an Outperform rating and $16.00 price target on Immatics (NASDAQ: IMTX).The analyst comments "IMTX reported ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
